Abstracts tagged "Drug toxicity"

Abstract Number: 0431 • ACR Convergence 2020
Hydroxychloroquine Use Was Not Associated with QTc Length in a Large Cohort of SLE and RA Patients
Elizabeth Park¹, Jon Giles², Thania Perez-Recio¹, Paloma Pina³, Christopher Depender¹, Joan Bathon¹ and Laura Geraldino-Pardilla⁴, ¹Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ²Columbia University, New York, NY, ³Cardiac Electrophysiology, Northwestern Medicine, Chicago, IL, ⁴Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE), and is used as monotherapy and combined with other DMARDs in rheumatoid arthritis…
Abstract Number: 1779 • ACR Convergence 2020
Gap in Contraceptive Education to Females with Rheumatic Disease on Teratogenic Medications
Andras Perl¹, Sundus Mian¹ and Jihad Ben Gabr¹, ¹SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Teratogenic disease-modifying anti-rheumatic disease modifying drugs (DMARDs) are often prescribed to women of childbearing age. Contraception represents an important area of reproductive health for female patients with…
Abstract Number: 0540 • ACR Convergence 2020
Risk of Hydroxychloroquine Retinopathy in the Community
Jesse Dabit¹, Mehmet Hocaoglu², Kevin Moder¹, Andrew Barkmeier³, Wendy Smith³, Thomas O'Byrne¹, Cynthia Crowson⁴ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center Midtown Campus, Baltimore, MD, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Hydroxychloroquine (HCQ) is used in the treatment of a wide variety of autoimmune diseases. HCQ retinopathy is a feared complication of long-term use. The…
Abstract Number: 1825 • ACR Convergence 2020
Risk Factors for Antimalarial-Induced Retinal Toxicity in Systemic Lupus Erythematosus and Other Rheumatic Diseases
Gemma Cramarossa¹, Hsin-Yen Liu² and Janet Pope³, ¹Western University, Kleinburg, ON, Canada, ²Western University, London, ON, Canada, ³Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada
Background/Purpose: Hydroxychloroquine (HCQ) and chloroquine (CQ) are antimalarial (AM) medications prescribed for a variety of rheumatic diseases, including systemic lupus erythematosus (SLE). Many patients will…
Abstract Number: 0588 • ACR Convergence 2020
Feast or Famine? An Institutional Assessment of Hydroxychloroquine Screening Practices
Alanna James¹, Kelli Kam¹, Vaneet Sandhu² and Christina Downey³, ¹Loma Linda University Health, Loma Linda, CA, ²Loma Linda University, Loma Linda, CA, ³Loma Linda University Medical Center, Redlands, CA
Background/Purpose: Hydroxychloroquine (HCQ) is a generally safe and widely used rheumatologic drug. Maculopathy is an adverse effect in < 1% in the first 5 years…
Abstract Number: 1830 • ACR Convergence 2020
Adverse Drug Reactions to Trimethoprim-sulfamethoxazole as a Prophylactic Agent Against Pneumocystis Pneumonia in Patients with Systemic Lupus Erythematosus: anti-Sm Antibody as a Possible Risk Factor
Shinji Izuka¹, Hiroyuki Yamashita², Yuko Takahashi² and Hiroshi Kaneko², ¹Devision of Rheumatic Disease, National Center for Global Health and Medicine, Toshima-Ku, Tokyo, Japan, ²Devision of Rheumatic Disease, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
Background/Purpose: Pneumocystis pneumonia (PCP) is a life-threatening infection in immunocompromised patients, including those with connective tissue diseases (CTDs), treated with corticosteroids or immunosuppressive agents. Trimethoprim-sulfamethoxazole…
Abstract Number: 0952 • ACR Convergence 2020
Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial
Puja Khanna¹, Dinesh Khanna¹, Gary Cutter², Jeffrey Foster², Joshua Melnick³, Sara Jaafar¹, Stephanie Biggers², AKM Rahman², Hui-Chen Kuo², Michelle Feese² and Kenneth Saag⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham (UAB), Vestavia Hills, AL, ⁴University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL
Background/Purpose: Pegloticase, a recombinant, pegylated uricase, is used for treatment of gout in patients who fail oral urate lowering therapy (ULT). Despite successful reduction of…
Abstract Number: 1844 • ACR Convergence 2020
Hydroxychloroquine and QTc Prolongation in a Cohort of SLE Patients
Mayce Haj-Ali¹ and H. Michael Belmont², ¹NYU Langone Health, new york, ²NYU School of Medicine, New York, NY
Background/Purpose: Hydroxychloroquine (HCQ) is an antimalarial drug used in the treatment of systemic lupus erythematous (SLE). Cardiac toxicity is very rare in SLE, but has…
Abstract Number: 1015 • ACR Convergence 2020
The Prevalence and Risk Factors for Liver Fibrosis Among Rheumatoid Arthritis (RA) Patients on Disease-Modifying Anti-rheumatic Drugs (DMARDs)
Chou Luan Tan¹, Boon Han Ng², Noor Shahrazat Ahmad², Shahrul Aiman Soelar², Muhammad Zulhilmi Asyraf Jazlan², Mohd Ammar Dzakirin Md Mansor², Mohd Azri Mohd Suan², Kuang Kiat Kiew², Zalwani Zainuddin², Muhammad Radzi Abu Hassan² and Chong Hong Lim², ¹Hospital Sultanah Bahiyah, Kementerian Kesihatan Malaysia, Alor Setar, Kedah, Malaysia, ²Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia
Background/Purpose: Majority of DMARDs, including methotrexate (MTX), leflunomide (LEF) and sulfasalazine (SSZ) arebelieved to be hepatotoxic, causing liver fibrosis. However, the clinical findings were inconsistent.…
Abstract Number: 1846 • ACR Convergence 2020
Evaluating the Risk of QT-prolongation Associated with Hydroxychloroquine Use with and Without Antidepressants in SLE Patients with Fibromyalgia
Jacinta Renaldi¹, Fotios Koumpouras¹ and Mei Xue Dong¹, ¹YALE SCHOOL OF MEDICINE, New Haven, CT
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease predominantly affecting woman of child-bearing age. Concurrent fibromyalgia syndrome (FMS) has been reported in…
Abstract Number: 1360 • ACR Convergence 2020
New-Onset Inflammatory Bowel Diseases Among IL-17 Inhibitors-Treated Patients: Results from the Case-Control MISSIL Study
Jean-Guillaume Letarouilly¹, Benjamin Pariente², Thao Pham³, Emilie Acquacalda⁴, Béatrice Banneville⁵, Sébastien Barbarot⁶, Elodie Bauer⁷, Pauline Baudart⁸, Pascal Claudepierre⁹, Arnaud Constantin¹⁰, Emmanuelle Dernis¹¹, Renaud Felten¹², Philippe Gaudin¹³, Céline Girard¹⁴, Bruno Gombert¹⁵, Philippe Goupille¹⁶, Xavier Guennoc¹⁷, Isabelle Henry-Desailly¹⁸, Denis Jullien¹⁹, Elena Karimova²⁰, Sylvain Lanot²¹, Loïc Le Dantec²², Tristan Pascart²³, Laurianne Plastaras²⁴, Nathalie Sultan-Bichat²⁵, Xavier Truchet²⁶, Stéphane Varin²⁷, Daniel Wendling²⁸, Lousie Gaboriau²⁹, Delphine Staumont-Sallé³⁰, Laurent Peyrin-Biroulet³¹ and René-Marc Flipo¹, ¹Univ-Lille, CHU Lille, department of rheumatology, Lille, France, ²Univ-Lille, CHU Lille, department of gastroenterology, Lille, France, ³Aix Marseille Univ, APHM, department of rheumatology, Marseille, France, ⁴CHPG, department of rheumatology, Monaco, Monaco, ⁵AP-HP, Hôpital Pitié-Salpêtrière, Service de Rhumatologie, Paris, 75013, Paris, France, ⁶CHU de Nantes, department of dermatology, Nantes, France, ⁷CHRU Nancy, department of rheumatology, VANDOEUVRE LES NANCY, Lorraine, France, ⁸CHU Caen, department of rheumatology, Caen, France, ⁹Hôpital Henri Mondor, Université Paris Est Créteil, EA 7379 EpiDermE, department of rheumatology, Créteil, France, ¹⁰Hospital Pierre Paul Riquet, Toulouse, France, ¹¹CH Le Mans, department of rheumatology, Le Mans, France, ¹²Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, France, ¹³CHU Grenoble, department of rheumatology, Grenoble, France, ¹⁴CHU Montpellier, department of rheumatology, Montpellier, France, ¹⁵CH La Rochelle, department of rheumatology, La Rochelle, France, ¹⁶CHU Tours, department of rheumatology, Tours, France, ¹⁷CH Saint-Brieuc, department of rheumatology, Saint-Brieuc, France, ¹⁸CHU Amiens, department of rheumatology, Amiens, France, ¹⁹CHU Lyon, department of dermatology, Lyon, France, ²⁰CH Lens, department of dermatology, Lens, France, ²¹CH Alençon, department of rheumatology, Alençon, France, ²²Ahnac, department of rheumatology, Hénin-Beaumont, France, ²³Ghicl, Hôpital Saint-Philibert, department of rheumatology, Lomme, France, ²⁴CH Colmar, department of gastroenterology, Colmar, France, ²⁵CH Ouest-Réunion, department of dermatology, Saint Paul, La Réunion, France, ²⁶HIA Sainte-Anne, department of gastroenterology, Toulon, France, ²⁷CHD Vendée, department of rheumatology, La Roche-sur-Yon, France, ²⁸CHU Besançon, department of rheumatology, Besancon, France, ²⁹Univ-Lille, CHU Lille, department of pharmacovigilance, Lille, France, ³⁰Univ-Lille, CHU Lille, department of dermatology, Lille, France, ³¹CHU Nancy, department of gastroenterology, VANDOEUVRE LES NANCY, Lorraine, France
Background/Purpose: A warning regarding safety of Interleukin 17 inhibitors (IL-17i) has been issued from data of randomized controlled trials (RCT) showing cases of new-onset inflammatory bowel…
Abstract Number: 2001 • ACR Convergence 2020
Adverse Effects of Low Dose Methotrexate: Adjudicated Hematologic Outcomes in a Large Randomized Double-blind Placebo-controlled Trial
Kathleen Vanni¹, Nancy Berliner¹, Nina Paynter², Robert Glynn², Jean MacFadyen¹, Joshua Colls¹, Fengxin Lu¹, Chang Xu², Paul Ridker¹ and Daniel H Solomon¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston
Background/Purpose: Low dose methotrexate (LD-MTX), a cornerstone in the treatment of rheumatoid arthritis, is associated with a moderately increased risk of anemia and leukopenia, but…
Abstract Number: 1494 • ACR Convergence 2020
Patient-Reported Adverse Events, Quality of Life and Treatment Adherence in Juvenile Idiopathic Arthritis: Analysis of Two Large International Cohorts
Alessandra Alongi¹, Maria Trachana², Valda Stanevicha³, Laura Marinela Ailioaie⁴, Elena Tsitsami⁵, Angelo Ravelli⁶, Alessandro Consolaro⁶ and Nicolino Ruperto⁷, ¹IRCCS Istituto Giannina Gaslini, Genoa, Italy, ²Aristotle University of Thessaloniki, Thessaloníki, Greece, ³Riga Stradins University, Riga, Latvia, ⁴Alexandru Ioan Cuza University of Iasi, Iasi, Romania, ⁵Aghia Sophia Childrens Hospital, Athens, Greece, ⁶Università degli Studi di Genova, Genoa, Italy, ⁷Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Juvenile idiopathic arthritis (JIA) patients may experience significant medication-related adverse effects (AEs), which may adversely affect health-related quality of life (HRQOL), daily activities and…
Abstract Number: 321 • 2019 ACR/ARP Annual Meeting
Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus
Tara Skorupa¹ and Robert Shmerling ¹, ¹Beth Israel Deaconess Medical Center / Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly prescribed medication for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other rheumatic diseases. However, HCQ may cause retinal…
Abstract Number: 1713 • 2019 ACR/ARP Annual Meeting
Drug-induced IgA Vasculitis: Data from the French Pharmacovigilance Network and the WHO VigiBase
CAMILLE RASMUSSEN¹, MYLENE TISSEYRE ², JULIE GARON-CZMIL ², MARINA ATZENHOFFER ³, Loïc Guillevin ⁴, LAURENT CHOUCHANA ² and Benjamin Terrier ⁴, ¹Cochin Hospital, National Referral Center for Rare Systemic Autoimmune Diseases, PARIS, PARIS, France, ²PHARMACOVIGILANCE, COCHIN HOSPITAL, PARIS, PARIS, France, ³PHARMACOVIGILANCE CENTER LYON, FRANCE, LYON, France, ⁴National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: IgA vasculitis (IgAV) is an immune complex small-vessel vasculitis, with IgA1-dominant immune deposits. Drug-induced IgAV were rarely reported in the literature, but no systematic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].